Author Archives: admin


Stem Cell Clinic > Articles by: admin

Brazilian HIV patient cured: Can this be true? – Deutsche Welle

By Stem Cell Treatment

The Sao Paulo patient is a 36-year-old man who finished an antiretroviral therapy treatment to specifically address HIV/AIDS in March 2019. The news raises myriad questions in the scientific community. Additionally, the data are preliminary and the case is particularly compelling because, of the five people who received the treatment, only one has been cured.

Jrgen Rockstroh, professor and doctor of medicine and the head of the outpatient Clinic for Infectious Diseases and Immunology at the Center for Integrated Oncology at the University Clinic in Bonn, said: "These are exciting findings, but they're very preliminary. This has happened to one person, and one person only, but it did not succeed in four others given the same treatment. Clearly, reproducibility of the findings or confirmation in an additional individual would be important."

If the case were proven, it would be a monumental discovery. However, Brazilian scientists say the results are yet to be confirmed, and testing is ongoing.

Why is it so difficult to cure HIV?

HIV inserts its genetic material into the DNA of its target immune cell obliging the cell to form copies of the virus. In this way, the HIV integrates itself directly into the DNA and literally becomes part of its host's body. This makes the virus incredibly difficult to treat.

HIV hides in those cells residing dormant in them for years before it wakes up and causes acquired immunodeficiency syndrome (AIDS). Some scientists believe that the dormant stage is an evolutionary advantage to the virus. In the sites where HIV first enters the body, there are few immune cells to infect.

If the virus destroys all these few existing cells immediately after invasion, there will be no immune cells left to carry the infection to further cells. Rather, the HIV delays its activation until it is carried by those cells initially infected to tissues where it can infect even more cells.

This process ensures a better chance for the virus to spread. This dormant or latent stage can last up to 12 years. After the virus wakes up, the immune system weakens, and AIDS develops. A weakened immune system leaves the patient prone to mild infections that an otherwise healthy individual would likely not develop.

Only two people have been completely cured from HIV

Two patients in London and Berlin underwent a risky bone marrow transplant from a very particular donor, who was discovered to have a natural immunity to HIV. The bone marrow from this individual is immune to the virus due to a mutation in one of the receptors of the immune cells that HIV must be able to enter to successfully cause AIDs.

Before the stem-cell transplantation, doctors destroyed the immune cells carrying the HIV virus in their DNA from the Berlin patient's bone marrow. Later, the naturally mutated stem-cells from the donor were transplanted. The procedure is precarious and can result in life threating conditions, such as graft-versus-host disease, where the body rejects the transplant.

While long-term remission was achieved in these two patients, a bone marrow transplant is not a viable cure for all cases. These patients underwent this experimental treatment to address cancer diagnoses.

How is HIV treated?

Antiretrovirals hinder viral replication, as well as attachment to target cells. The purpose is to stop any viral activity and viral production. Currently, antiretroviral therapy can decrease the viral load in the body to an extent that the person is no longer infectious.

Read more:Stem cell transplants and HIV: What you need to know

If the viral load remains undetectable, one could have unprotected sex without infecting their partner. Moreover, HIV would not be transmitted from a mother to a child in this case. However, if the antiretroviral therapy is stopped, the control of virus replication ends.

The So Paulo patient received antiretrovirals. When asked whether it is possible to expect a complete elimination of a virus which integrates itself in the DNA by antiretroviral drugs, Dr. Rockstroh said, "numerous studies including intensified 3-drug therapy (including maraviroc and dolutegravir given to the Brazilian patient) even very early in HIV-infection were not able to achieve viral elimination or even decrease reservoir over time in multiple clinical trials."

Dr. Rockstroh explained that patients taking post-treatment controllers showed no signs of restarted viral replication for over one year after interrupting anti-retroviral therapy. However, the complete elimination of the virus has not been found in these patients.

How does the immune system react?

The physician added, "As each individual immune system reacts very differently and the spectrum of immune response ranges from rapid disease progression to elite controllers who have no signs of ongoing replication in plasma over years without treatment makes single cases very difficult to generalize from."

The So Paulo patient received a cocktail of antiretroviral drugs, including nicotinamide, a form of vitamin B3, which is thought to wake up the hidden virus and lure it out of its reservoirs. This is done to highlight infected cells for other drugs, so the immune system can kill the virus.

Dr. Rockstroh suggested the approach of virus activation could be significant in finding a functional cure for HIV. Whether this approach works or contributes to this specific case is still unknown.

Scientists are questioning the case and raising the concerns that the patient may have continued to take antiretroviral drugs without the knowledge of the study team. The team commented that they plan to check his blood for antiviral drugs to rule out this possibility.

What is also intriguing about the case is the loss of HIV antibodies. Dr. Rockstroh suggested that the weakening of the antibody test overtime is due to a diminishing immune response. However, the reasons for this remain unclear and require further testing.

Former South African president Thabo Mbeki (1999 - 2008) went down in history as the foremost African denier of AIDS. Against all scientific evidence he maintained that HIV did not cause AIDS. He instructed his health officials to combat the disease with herbal remedies. Experts believe his denialism cost up to 300,000 lives. Some have called for Mbeki to be tried for crimes against humanity.

In 2007 former Gambian president Yahya Jammeh (1996 - 2017) forced AIDS patients to undergo a cure that he had personally developed. It turned out to be a concoction based on herbs; an unknown number of people died. Jammeh, who claimed that he had mystic powers, is the first African head of state to be tried for violating the rights of HIV-positive people.

Another former South African head of state to make headlines for an unconventional take on AIDS was Jacob Zuma (2009 - 2018). After being charged with raping an HIV-positive woman in 2006, Zuma said he was not at risk of infection, despite not using a condom, because he had "taken a shower afterwards." In 2010 he disclosed the negative results of his AIDS test, to fight the stigma, he said.

Ugandas President Yoweri Museveni took his time before joining the fight against the epidemic. As late as 2004, during an international AIDS conference in Thailand, he downplayed the effectiveness of condoms, alleging, among other things, that they ran counter to some African sexual practices. "We dont think we can become universally condomised," he said. His remarks were met with laughter.

Some action taken by African heads of state to fight the scourge did not go down well at home. A tax introduced in 1999 by Zimbabwe's President Robert Mugabe (1987-2017) to help orphans and sufferers met with resistance. It is still in place today. In 2004 Mugabe admitted that his own family had been affected by AIDS. He said the disease was "one of the greatest challenges facing our nation."

Fear of economic repercussions affecting, for example, tourism, is one reason why African leaders have been reluctant to acknowledge the threat. But President Kenneth Kaunda of Zambia (1964-1991) announced as early as 1987 that one of his sons had died of AIDS. In 2002 he was the first African leader to take an AIDS test. He still fights against AIDS today.

The fight against AIDS by Kaundas successor Edgar Lungu met with some hitches when he tried to make AIDS-testing compulsory in Zambia. Lungu said in 2016 that the policy was non-negotiable. But a huge outcry in Zambia and abroad forced him to backpedal especially as the World Health Organization made clear that compulsion encourages the stigmatization of HIV-positive people.

After leaving office, Festus Mogae, former president of Botswana (1998-2008), launched Champions for an AIDS-Free Generation, which brings together a number of former African presidents and other influential personalities eager to help fight the scourge. They hope that their experience and influence will enable them to exert pressure on governments and partners to invest in AIDS prevention.

Author: Cristina Krippahl

Here is the original post:
Brazilian HIV patient cured: Can this be true? - Deutsche Welle

COVID-19 Imparts Positive Impact on Stem Cell Therapy Market | 2020-2027 – Cole of Duty

By Stell Cell Research

The stem cell therapy marketwas valued at US$ 1,534.55 million in 2019 and is expected to grow at a CAGR of 16.7% from 2020to 2027 to reach US$ 5,129.66 million by 2027.

The Insight Partners provides you global research analysis on Stem Cell Therapy Market and forecast to 2027. The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Stem Cell Therapy Market during the forecast period, i.e., 20202027.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Stem Cell Therapy Market. The researcher provides an extensive analysis of the Stem Cell Therapy Market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Get Sample Copy of Stem Cell Therapy Market at: https://www.theinsightpartners.com/sample/TIPHE100000991/

Major key players covered in this report:

Report Offerings:

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Stem Cell Therapy Market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Stem Cell Therapy Market segments and regions.

The research on the Stem Cell Therapy Market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Stem Cell Therapy Market on the basis of end user, product type, application, and demography for the forecast period 20202027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Stem Cell Therapy Market.

Stem Cell Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPHE100000991/

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Here is the original post:
COVID-19 Imparts Positive Impact on Stem Cell Therapy Market | 2020-2027 - Cole of Duty

Gene therapy or immunotherapy: which approach is more likely to deliver a cure for HIV? – aidsmap

By Stell Cell Research

Amidst speculation that a five-drug antiretroviral regimen and nicotinamide might have cured HIV in one man, researchers debated whether gene therapy or immunotherapy is more likely to lead to an HIV cure that can be delivered to millions during the AIDS 2020 Cure pre-conference last week.

A cure for HIV could take two forms, either a treatment or procedure that can eradicate the virus from the body or one which can keep the virus under control without the need for antiretroviral drugs remission, in the parlance of the field.

Eradication of HIV is challenging because the virus inserts its DNA into long-lived cells in the body where it may lie dormant for decades - the so-called HIV reservoir. All this virus needs to be found, activated and purged, but presentations at AIDS 2020 show that the reservoir is more complex than previously assumed.

A unit of heredity, that determines a specific feature of the shape of a living organism. This genetic element is a sequence of DNA (or RNA, for viruses), located in a very specific place (locus) of a chromosome.

A type of experimental treatment in which foreign genetic material (DNA or RNA) is inserted into a person's cells to prevent or fight disease.

Use of immunologic agents such as antibodies, growth factors, and vaccines to modify (activate, enhance, or suppress) the immune system in order to treat disease. It is applied in the cancer field and in HIV research (attempts to eliminate the virus). Immunotherapy is also used to diminish adverse effects caused by some cancer treatments or to prevent rejection of a transplanted organ or tissue.

To eliminate a disease or a condition in an individual, or to fully restore health. A cure for HIV infection is one of the ultimate long-term goals of research today. It refers to a strategy or strategies that would eliminate HIV from a persons body, or permanently control the virus and render it unable to cause disease. A sterilising cure would completely eliminate the virus. A functional cure would suppress HIV viral load, keeping it below the level of detection without the use of ART. The virus would not be eliminated from the body but would be effectively controlled and prevented from causing any illness.

The HIV reservoir is a group of cells that are infected with HIV but have not produced new HIV (latent stage of infection) for many months or years. Latent HIV reservoirs are established during the earliest stage of HIV infection. Although antiretroviral therapycan reduce the level of HIV in the blood to an undetectable level, latent reservoirs of HIV continue to survive (a phenomenon called residual inflammation). Latently infected cells may be reawakened to begin actively reproducing HIV virions if antiretroviral therapy is stopped.

HIV is distributed across numerous tissues in the body, not just cells in the blood or lymph nodes, an autopsy study by the US National Institutes for Allergy and Infectious Disease shows. Predicting which tissues are the most important reservoirs is difficult, as the small study showed big variation between individuals.

Furthermore, the normal work of CD4 memory cells activation and proliferation in response to pathogens inevitably leads to cloning of cells containing HIV DNA and an increase in intact HIV DNA capable of producing new virus over time, Bethany Horsburgh of Australias Centre for Virus Research at Westmead Institute for Medical Research reported.

Even very early antiretroviral treatment appears unable to halt the development of a reservoir that can sustain SIV infection in the body, Dr Henintsoa Rabazantahary of Canadas Universit Laval told the conference. Her macaque study began treating some animals four days after infection, underscoring how quickly an intractable reservoir is established.

These findings emphasise the importance of approaches to curing HIV that go beyond the `shock and kill` regimens designed to activate HIV-infected cells, which have shown disappointing results in clearing the reservoir.

Gene therapy to eradicate HIV or immunotherapy to contain HIV are being explored as potential approaches but which is more likely to be successful? Two leading cure researchers debated the merits of the approaches at a pre-conference HIV cure workshop last week.

Professor Sharon Lewin, Director of the Doherty Institute of Infection and Immunity at the University of Melbourne argues that gene therapy is more likely to deliver an HIV cure than immunotherapeutic approaches aimed at long-term remission of HIV. Proof of concept for a gene therapy approach already exists, she said, in the form of the Berlin and London patients, Timothy Brown and Adam Castellijo, who were cured of HIV after stem cell transplants from donors with the CCR5 delta 32 mutation that confers resistance to HIV infection of cells.

Gene therapy can be used against multiple targets to engineer protection against HIV infection of cells, to purge the virus from infected cells and enhance immune defences that attack HIV.

But the big challenge for gene therapy is to develop an approach that doesnt require cells to be taken out of the body for gene editing in the laboratory. Almost all gene therapy studies underway are using this 'ex vivo' approach, which harvests cells, edits them in the laboratory and then returns them to the patients body. Although the ex vivo approach has already been proved to work, both for HIV and cancer immunotherapy using CAR T-cells, its expensive and requires state of the art laboratory equipment.

The alternative, in vivo gene therapy, would require nanoparticles or a vector such as adenovirus to deliver the edited gene to cells. One study has already shown that its possible to achieve sustained production of a broadly neutralising antibody against HIV, VRC07, using an adenovirus vector to deliver an antibody gene.

Elimination of host stem cells, achieved in the cases of the Berlin and London patients through gruelling chemotherapy prior to bone marrow transplants, might soon be achievable through antibodies-drug conjugates that would target stem cells, Lewin suggested.

Professor John Frater of the University of Oxford sees immunotherapy as more likely to deliver long-term remission. He argued that gene therapy is still largely unproven in any field and the long-term safety of gene therapy is still unclear. In contrast, immunotherapies are already being used to treat cancers such as melanoma and lymphoma, as well as rheumatoid arthritis. Elite controllers of HIV, or long-term non-progressors, also offer evidence that the immune system can control HIV in some circumstances.

Immunity is the best machine you could imagine its had millions of years of R & D so we should use it and make the most of it, he said. Do not confuse the failure of vaccines so far as a red flag for immunotherapy. A vaccine needs to target a rapidly mutating, fast-replicating virus, whereas an immunotherapy targets a stable antigen that is less prone to mutate the cells in the HIV reservoir. We need to think of it more like a strategy for cancer than infection, he said.

Broadly neutralising antibodies represent one promising avenue of immunological research, along with therapeutic vaccination or anti-PD1 to activate exhausted host defences, Professor Miles Davenport of the Kirby Institute of Immunity & Infection, Australia, told a symposium on emerging cure strategies.

But he warned that we still dont understand how immune control relates to viral rebound and how much the HIV reservoir might need to be reduced to make immunological control of HIV viable. What might overcome this challenge, he suggested, would be gene therapy approaches that could render 90% of cells resistant to infection. Modelling by his research group suggest that this level of transduction of cells would dramatically limit viral rebound, permitting immunological control of HIV.

In summary, it may not be a question of choosing between gene therapy or immunotherapy, but using both approaches to achieve HIV remission.

References

Rabezanahary H et al. Contribution of monocytes and CD4 T cell subsets in maintaining viral reservoirs in SIV-infected macaques treated early after infection with antiretroviral drugs. 23rd International AIDS Conference abstract OA004, 2020.

Horsburgh H et al. Cell proliferation contributes to the increase of genetically intact HIV over time. 23rd International AIDS Conference abstract OA005, 2020.

Imamichi H et al. Multiple sanctuary sites for intact and defective HIV-1 in post-mortem tissues in individuals with suppressed HIV-1 replication: Implications for HIV-1 cure strategies. 23rd International AIDS Conference abstract 0A006, 2020.

S Lewin & J Frater. Gene therapy vs. immunotherapy: which is more likely to work? Debate. AIDS 2020 Virtual, HIV Cure pre-conference.

Davenport M. The promise of immunotherapy in HIV infection. AIDS 2020 Virtual symposium presentation, 'Pushing the boundaries: new approaches to a cure'.

See the original post:
Gene therapy or immunotherapy: which approach is more likely to deliver a cure for HIV? - aidsmap

Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners – BusinessGhana

By Somatic Stem Cells

The 2020 award celebrates outstanding research in rare diseases Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) and the New York Academy of Sciences announced today the Winners of the third annual Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of rare disease research.

Each Winner receives a prize of US $200,000.

This press release features multimedia.

View the full release here: https://www.

businesswire.

com/news/home/20200708005039/en/ The 2020 Winner of the Senior Scientist Award is Adrian R.

Krainer, Ph.

D.

, St.

Giles Foundation Professor at Cold Spring Harbor Laboratory.

Prof.

Krainer is recognized for his outstanding research on the mechanisms and control of RNA splicing, a step in the normal process by which genetic information in DNA is converted into proteins.

Prof.

Krainer studies splicing defects in patients with spinal muscular atrophy (SMA), a devastating, inherited pediatric neuromuscular disorder caused by loss of motor neurons, resulting in progressive muscle atrophy and eventually, death.

Prof.

Krainers work culminated notably in the development of the first drug to be approved by global regulatory bodies that can delay and even prevent the onset of an inherited neurodegenerative disorder.

Collectively, rare diseases affect millions of families worldwide, who urgently need and deserve our help.

Im extremely honored to receive this recognition for research that my lab and our collaborators carried out to develop the first approved medicine for SMA, said Prof.

Krainer.

As basic researchers, we are driven by curiosity and get to experience the thrill of discovery; but when the fruits of our research can actually improve patients lives, everything else pales in comparison.

The 2020 Winner of the Early-Career Scientist Award is Jeong Ho Lee, M.

D.

, Ph.

D, Associate Professor, Korea Advanced Institute of Science and Technology (KAIST).

Prof.

Lee is recognized for his research investigating genetic mutations in stem cells in the brain that result in rare developmental brain disorders.

He was the first to identify the causes of intractable epilepsies and has identified the genes responsible for several developmental brain disorders, including focal cortical dysplasias, Joubert syndromea disorder characterized by an underdevelopment of the brainstemand hemimegalencephaly, which is the abnormal enlargement of one side of the brain.

Prof.

Lee also is the Director of the National Creative Research Initiative Center for Brain Somatic Mutations, and Co-founder and Chief Technology Officer of SoVarGen, a biopharmaceutical company aiming to discover novel therapeutics and diagnosis for intractable central nervous system (CNS) diseases caused by low-level somatic mutation.

It is a great honor to be recognized by a jury of such globally respected scientists whom I greatly admire, said Prof.

Lee.

More importantly, this award validates research into brain somatic mutations as an important area of exploration to help patients suffering from devastating and untreatable neurological disorders.

The 2020 Winners will be honored at the virtual Innovators in Science Award Ceremony and Symposium in October 2020.

This event provides an opportunity to engage with leading researchers, clinicians and prominent industry stakeholders from around the world about the latest breakthroughs in the scientific understanding and clinical treatment of genetic, nervous system, metabolic, autoimmune and cardiovascular rare diseases.

At Takeda, patients are our North Star and those with rare diseases are often underserved when it comes to the discovery and development of transformative medicines, said Andrew Plump, M.

D.

, Ph.

D.

, President, Research & Development at Takeda.

Insights from the ground-breaking research of scientists like Prof.

Krainer and Prof.

Lee can lead to pioneering approaches and the development of novel medicines that have the potential to change patients lives.

Thats why we are proud to join with the New York Academy of Sciences to broadly share and champion their workand hopefully propel this promising science forward.

Connecting science with the world to help address some of societys most pressing challenges is central to our mission, said Nicholas Dirks, Ph.

D.

, President and CEO, the New York Academy of Sciences.

In this third year of the Innovators in Science Award we are privileged to recognize two scientific leaders working to unlock the power of the genome to bring innovations that address the urgent needs of patients worldwide affected by rare diseases.

About the Innovators in Science Award The Innovators in Science Award grants two prizes of US $200,000 each year: one to an Early-Career Scientist and the other to a well-established Senior Scientist who have distinguished themselves for the creative thinking and impact of their research.

The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising Early-Career Scientists and their most outstanding Senior Scientists working in one of four selected therapeutic fields of neuroscience, gastroenterology, oncology, and regenerative medicine.

Prize Winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines.

The New York Academy of Sciences administers the Award in partnership with Takeda.

For more information please visit the Innovators in Science Award website.

About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI).

We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.

takeda.

com.

About the New York Academy of Sciences The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide.

With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity.

The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions and increase the number of scientifically informed individuals in society at large.

Please visit us online at www.

nyas.

org.

.

Read more:
Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - BusinessGhana

Tribute to Andra Campbell after five-year cancer battle | Romsey Advertiser – Romsey Advertiser

By Stem Cell Doctors

A MOTHER has paid tribute to her brave star who passed away this week after a five-year battle with cancer.

Andra Campbell was diagnosed with acute myeloid leukaemia after collapsing at her Roman Way home in August of 2015.

As reported in the Advertiser, a global search for a blood donor was later launched after it was discovered that she had rare blood cells due to her grandfathers St Lucian heritage.

Andra underwent a bone marrow transplant when her father, Paul, was found to be a suitable stem cell donor, and had been undergoing clinical trials at Oxford.

However, after the cancer returned for a third time she was told it was terminal. She died at the age of 33 on Saturday, July 4.

Andras mother, Beverley, has since paid tribute to her well-loved daughter and the legacy she leaves behind.

She was somebody who lived for life, said her mother, Beverley. She went all around the world, she travelled, she has friends all over. She was just the life and soul of the party.

Its incredible how many people she knew and how many people she touched. She was just a fun loving girl who touched a lot of hearts. And she fought hard. She had three lots of trying to get better, but it just didnt work for her.

The familys search for a blood donor took them to all corners of the globe.

From America to South Africa, they also shared an appeal on Asian radio station, before two possible matches from Israel were found, only to then fail a medical check.

Earlier this year she was readmitted to Basingstoke hospital, however her family were unable to be with her due to the Covid-19 situation. They were eventually told she had just days to live.

We had to listen to that over the phone because we werent allowed to be with her, he mother said. That poor little girl was just stuck there. She was all on her own even though people were desperate to be with her. It was heart-breaking.

She later returned home, surrounded by her closest friends and family, where she defied doctors expectations one more time.

All her friends from London came down and camped out, said Beverley.

The doctors said she would die within hours but she held on for another four days.

She was a fighter all the way - five years that girl fought for.

She just couldnt carry on. She was in so much pain.

She was well-loved and shes left a lot of people very heartbroken.

Originally posted here:
Tribute to Andra Campbell after five-year cancer battle | Romsey Advertiser - Romsey Advertiser

Another four biotechs scratch out the first number and ask for more as IPO boom continues – Endpoints News

By Stem Cell Clinic

Four more biotechs are raising their offers in an already record year for biotech IPOs.

Softbank-backed Relay Therapeutics scratched out its original $200 million filing and proposed a $250 million raise that would make them a $1.5 billion company. CAR-T developer Poseida Therapeutics bumped itself up $74 million to $224 million. Off-the-shelf cell therapy startup Nkarta upped from $150 million to $215 million and then priced even higher, at $252 million. Frances Inventiva did its own modest reset, raising its bar from $102 million to $108 million.

Poseida, Nkarta and Inventiva priced today. Relay will price next week.

Barring a surprise flop, the latest flurry of raisesmeans there will be 13 $200 million-plus biotech IPOs in 2020 before August. By contrast, all of 2019 saw two biotechs pass that mark; 2018 saw 7 do so.

The run of eye-catching deals began in the first days of April when, after a pair of pandemic-driven stock market crashes, the small and little-known biotech Zentalis managed to score $165 million in a public offering. At the time, Nasdaqs Jordan Saxe told Bloomberghe expected biotech to open the IPO market back up, with its investors more focused on the long term than a short term that had the potential to be brutal. He predicted 30-35 IPOs for $3.5 billion and a series of blank check companies, a pair of predictions that have since looked prescient.

Its not just private companies that are getting in on the action. Public biotechs, too, have put out for large raises. This week alone Vir Biotechnology offered $300 million in a secondary offering, Revolution Medicines offered $156 million and Akero Therapeutics offered $188.2 million.

The buzz has allowed, among other things, very early stage companies to attract significant interest, including a single week in June when three preclinical biotechs raised over $200 million in a single week.

That trend has continued into this week. Nkarta, focused on natural killer cell therapies, has yet to bring a candidate into the clinic, although they plan to do so later this year. Relay Therapeutics, focused on solid tumors, only started their first trial earlier this year.

Poseida and Inventiva, though, are further along. With backing from Novartis, Poseidas BCMA CAR-T is already in Phase II and, earlier this year, they started recruiting for a Phase I with another CAR-T therapy. Inventiva is in Phase II for a NASH drug and a mucopolysaccharidosis type VI drug.

Read more:
Another four biotechs scratch out the first number and ask for more as IPO boom continues - Endpoints News

Hematopoietic Stem Cell Transplantation (HSCT) Market Demand Analysis and Projected huge Growth by 2025 – Daily Research Advisor

By Stell Cell Research

UpMarketResearch offers a latest published report on Global Hematopoietic Stem Cell Transplantation (HSCT) Market industry analysis and forecast 20192025 delivering key insights and providing a competitive advantage to clients through a detailed report. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report contains XX pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Hematopoietic Stem Cell Transplantation (HSCT) Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Hematopoietic Stem Cell Transplantation (HSCT) global status and trend, market size, share, growth, trends analysis, segment and forecasts from 20192025.

Get FREE Exclusive PDF Sample Copy Of This Report: https://www.upmarketresearch.com/home/requested_sample/30593

The scope of the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are represented in graphical format for a clear understanding on facts and figures.

Customize Report and Inquiry for The Hematopoietic Stem Cell Transplantation (HSCT) Market Report: https://www.upmarketresearch.com/home/enquiry_before_buying/30593

The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders. Secondary research techniques are implemented for better understanding and clarity for data analysis.

The Report Segments for Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis & Forecast 20192025 are as: Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by Products Allogeneic Autologous

Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by Applications Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

The Major Players Reported in the Market Include: Regen Biopharma Inc China Cord Blood Corp CBR Systems Inc Escape Therapeutics Inc Cryo-Save AG Lonza Group Ltd Pluristem Therapeutics Inc ViaCord I

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market industry Analysis and Forecast 20192025 helps the clients with customized and syndicated reports holding a key importance for professionals entailing data and market analytics. The report also calls for market driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real time scenario.

Key Reasons to Purchase:

Ask for Discount on Hematopoietic Stem Cell Transplantation (HSCT) Market Report at: https://www.upmarketresearch.com/home/request_for_discount/30593

UpMarketResearch offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Website https://www.upmarketresearch.com Address 500 East E Street, Ontario, CA 91764, United States.

Continued here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Demand Analysis and Projected huge Growth by 2025 - Daily Research Advisor

Food Poisoning Bacteria Causes Autoimmunity and May Be Linked to Alzheimers and Parkinsons – Technology Networks

By Stell Cell Research

Credit: Pixabay.

Read Time:

Salmonella was previously thought to only form biofilms in the environment, such as on food processing surfaces. Biofilms are dense collections of bacteria that stick together on surfaces to protect the bacteria from harsh conditions, including antibiotics and disinfectants. Detecting biofilms in an animal during an infection was a surprise.

In research published today in PLoS Pathogens, a VIDO-InterVac team led by Dr. Aaron White (PhD) discovered that salmonella biofilms were formed in the intestines of infected mice. For the study, the team used a mouse model to replicate human food-borne illness and showed that a biofilm protein called curlithat grows on the surface of bacteriawas connected to negative health outcomes.

Curli are a special type of protein called amyloids. Similar human proteins have been associated with neurodegenerative diseases such as Alzheimers disease, Parkinsons disease, and Amyotrophic lateral sclerosis (ALS, or Lou Gehrigs disease). Scientists don't know how these diseases start, but have speculated that something must trigger the accumulation of amyloids.

We are the first to show that a food-borne pathogen can make these types of proteins in the gut, said White, a leading expert on salmonella biofilms and curli amyloids.

There has been speculation that bacteria can stimulate amyloid plaque formation in Alzheimers, Parkinsons and ALS and contribute to disease progression. The discovery of curli in the gut could represent an important link, pointing to a potentially infectious cause for these diseases.

Collaborator Dr. agla Tkel (PhD) and her team from Temple University determined that the presence of curli led to autoimmunity and arthritistwo conditions that are known complications of salmonella infections in humans.

In mice, these reactions were triggered within six weeks of infection, demonstrating that curli can be a major driver of autoimmune responses, said Tkel.

The next step in the research is to confirm that this also occurs in humans, and test if other food-borne pathogens related to salmonella can cause similar autoimmune reactions.

This important discovery suggests that food-borne pathogens could initiate or worsen autoimmunity and have the potential to contribute to amyloid disorders such as Alzheimers and Parkinsons disease, said VIDO-InterVac Director Dr. Volker Gerdts (DVM).

ReferenceIn vivo synthesis of bacterial amyloid curli contributes to joint inflammation during S. Typhimurium infection. Amanda L. Miller et al. PLOS Pathogens,July 9, 2020, https://doi.org/10.1371/journal.ppat.1008591.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post here:
Food Poisoning Bacteria Causes Autoimmunity and May Be Linked to Alzheimers and Parkinsons - Technology Networks

Global and Country Specific Cell Proliferation Kit Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and Recovery Top…

By Stell Cell Research

Global Cell Proliferation Kit Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Cell Proliferation Kit market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/medical-devicesconsumables/cell-proliferation-kit-market-report

Global Cell Proliferation Kit Market: Product analysis: Colorimetric Detection Method, Fluorescent Detection Method, Others

Global Cell Proliferation Kit Market: Application analysis: Clinical, Industrial & Applied Science, Stem Cell Research

Major Market Players with an in-depth analysis: Biological Industries, Thermo Fisher Scientific, Sigma Aldrich (Merck), BD Biosciences, GE, PerkinElmer, Millipoore (Merck), Bio Rad, Biotium

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Cell Proliferation Kit market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Cell Proliferation Kit Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/cell-proliferation-kit-market-report#download_report

The Cell Proliferation Kit industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Cell Proliferation Kit research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Cell Proliferation Kit industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Cell Proliferation Kit Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Cell Proliferation Kit Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/medical-devicesconsumables/cell-proliferation-kit-market-report#download_report.

Cell Proliferation Kit Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Cell Proliferation Kit market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Cell Proliferation Kit Market as it consists all the information regarding the Cell Proliferation Kit market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Cell Proliferation Kit Market Report 2020 (Coronavirus Impact Analysis on Cell Proliferation Kit Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19. (*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/medical-devicesconsumables/cell-proliferation-kit-market-report

Read more:
Global and Country Specific Cell Proliferation Kit Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and Recovery Top...

Stem Cell Antibody to Garner Brimming Revenues by 2019-2025 – Cole of Duty

By Stell Cell Research

In this report, the global Stem Cell Antibody market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Stem Cell Antibody market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell Antibody market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2713516&source=atm

Segment by Type, the Stem Cell Antibody market is segmented into Primary Antibodies Secondary Antibodies

Segment by Application, the Stem Cell Antibody market is segmented into Proteomics Drug Development Genomics

Regional and Country-level Analysis The Stem Cell Antibody market is analysed and market size information is provided by regions (countries). The key regions covered in the Stem Cell Antibody market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Stem Cell Antibody Market Share Analysis Stem Cell Antibody market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Stem Cell Antibody business, the date to enter into the Stem Cell Antibody market, Stem Cell Antibody product introduction, recent developments, etc.

The major vendors covered: Thermo Fisher Scientific, Inc. (U.S.) Merck Group (Germany), Abcam plc (U.K.) Becton, Dickinson and Company (U.S.) Bio-Rad Laboratories, Inc. (U.S.) Cell Signaling Technology, Inc. (U.S.) Agilent Technologies, Inc. (U.S.) F. Hoffmann-La Roche Ltd (Switzerland) Danaher Corporation (U.S.) GenScript (U.S.), PerkinElmer, Inc. (U.S.) Lonza (Switzerland), and BioLegend, Inc. (U.S.)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2713516&source=atm

The study objectives of Stem Cell Antibody Market Report are:

To analyze and research the Stem Cell Antibody market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Stem Cell Antibody manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Stem Cell Antibody market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2713516&licType=S&source=atm

See the article here:
Stem Cell Antibody to Garner Brimming Revenues by 2019-2025 - Cole of Duty

→←